Sobi's TRYNGOLZA Gains CHMP Nod for Severe Hypertriglyceridemia

  • CHMP recommends approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia (sHTG) in the EU, ahead of schedule.
  • Phase 3 CORE and CORE2 studies showed a 72% reduction in triglyceride levels and 85% reduction in acute pancreatitis events.
  • European Commission decision expected in Q4 2026; TRYNGOLZA would be the first RNA-targeted therapy for sHTG in the EU.
  • Sobi holds exclusive commercialization rights outside the US, excluding Canada and China, under a license agreement with Ionis.

Sobi's positive CHMP opinion for TRYNGOLZA marks a significant milestone in the treatment of severe hypertriglyceridemia, a condition affecting approximately 700,000 people in the EU5 with triglyceride levels ≥880 mg/dL. The approval would solidify Sobi's leadership in rare disease therapies and expand its portfolio of RNA-targeted treatments. The strategic collaboration with Ionis Pharmaceuticals underscores the growing importance of targeted RNA therapies in addressing metabolic disorders.

Regulatory Timing
Whether the European Commission will approve TRYNGOLZA by the end of Q4 2026, as anticipated.
Commercial Strategy
How Sobi plans to position TRYNGOLZA in the EU market, given its first-to-market status for RNA-targeted therapies in sHTG.
Clinical Impact
The long-term efficacy and safety of TRYNGOLZA in reducing acute pancreatitis events and improving patient outcomes.